Description

Soritmik (sotalol hydrochloride) tablets 0.08 g. №20

Ingredients

Active ingredient: Sotalol hydrochloride 0.08 g per tablet.

Dosage

Dosage: The usual adult dose is **80-160 mg** twice daily. Dosage should be individualized based on the patient’s condition and response.

Indications

Indications: Soritmik tablets are indicated for the treatment of documented ventricular arrhythmias and certain supraventricular arrhythmias.

Contraindications

Contraindications: Soritmik tablets are contraindicated in patients with bronchial asthma, sinus bradycardia, heart block greater than first degree, and other conditions. Consult a healthcare professional for a full list of contraindications.

Directions

Directions: Take Soritmik tablets exactly as prescribed by your healthcare provider. Do not exceed the recommended dose without medical supervision.

Scientific Evidence

Sotalol hydrochloride, the active ingredient in Soritmik tablets, is a non-selective beta-adrenergic receptor blocker with Class III antiarrhythmic properties. It prolongs the action potential duration and refractory period in cardiac tissues, thereby exerting an antiarrhythmic effect. Studies have shown that sotalol is effective in the management of various types of arrhythmias, including atrial fibrillation and ventricular tachycardia.

Additional Information

Soritmik tablets should be used with caution in patients with renal impairment as dosage adjustments may be necessary. It is important to monitor electrolytes and renal function regularly during treatment with sotalol. Additionally, Soritmik may interact with other medications, so inform your healthcare provider about all the drugs you are taking.

Research studies have highlighted the efficacy of sotalol in reducing the recurrence of atrial fibrillation and improving overall heart rate control. Clinical trials have demonstrated the safety and effectiveness of sotalol in managing arrhythmias, making it a valuable option in the treatment of cardiac rhythm disorders.

Compared to other antiarrhythmic agents, sotalol has shown comparable efficacy in controlling arrhythmias while offering a favorable safety profile. Its unique pharmacological properties make it a preferred choice for certain patients with specific arrhythmic conditions.